Etanercept found to be ineffective in treating alcoholic hepatitis
The naturally high levels of leptin in diabetic patients may reduce the effectiveness of drug-eluting stents used to treat heart blockages, but using a chemical that differs from the one commonly used to coat stents could counteract this effect. The work by researchers at Columbia University Medical Center could potentially improve outcomes in diabetics who
Full Post: Cardiac stent patients with diabetes may benefit from drug that counteracts the effects of leptin
A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study are published in the December issue of Gastroenterology.
Alcoholic hepatitis is a major cause of morbidity and mortality worldwide. Severe alcohol-related liver disease carries a poor prognosis. Several research studies have worked to find a successful treatment for alcoholic hepatitis, but no consensus has been reached on the most effective treatment regimen.
“Alcohol usage has long been associated with serious liver diseases such as hepatitis,” says Vijay Shah, M.D., a Mayo Clinic hepatologist and lead researcher on the study. “The relationship between drinking and alcoholic hepatitis is complex. Not all heavy drinkers develop alcoholic hepatitis, and the disease can sometimes occur in people who drink only moderately. Though damage from alcoholic hepatitis often can be reversed if patients stop drinking, the disease can progress to cirrhosis and liver failure.”
In this placebo-controlled clinical trial, Mayo researchers collaborated with seven other medical centers to enroll 48 patients with moderate to severe alcoholic hepatitis. Patients were either given a placebo or etanercept, a compound which blocks the effects of toxic cytokines. Etanercept is approved for treatment of inflammatory arthritis and is under investigation for effectiveness in treating other inflammatory conditions. Research results found a significantly higher rate of six-month mortality in patients with moderate to severe alcoholic hepatitis who received etanercept. The six-month mortality rate was more than double that of the placebo group. The major cause was an increased rate of infections.
“Etanercept therapy showed promise in our animal models, but was not effective in treatment of patients with alcoholic hepatitis. A few possible causes of increased late mortality rate may relate to impaired liver regeneration, and another is the effects of etanercept on immune function,” says Dr. Shah.
Liver disease complications from alcohol are typically severe and difficult to treat, which further emphasizes the importance of not drinking too much.
“Despite awareness of hepatitis C and non-alcoholic fatty liver syndrome, our recent studies show that alcoholic liver disease is still the major cause of liver disease and liver-related death,” says Dr. Shah. “Our Mayo Clinic research team will continue to examine other avenues of treatment for alcoholic hepatitis patients — including examining other anti-inflammatory proteins for study purposes.”
Complete abstinence from alcohol is the single most important treatment for alcoholic hepatitis. It’s the only way to reverse liver damage or, in more advanced cases, to reduce the chance that the disease will become worse. Without abstinence, the majority of people with alcoholic hepatitis eventually develop cirrhosis and die, says Dr. Shah.
An NIH funded multi-center clinical trial found no benefit from “maintenance therapy,” low-dose peginterferon used for hepatitis C patients who have not responded to an initial round of treatment. In addition, the study showed a surprising health decline in patients with liver disease over the course of four years. A Saint Louis University researcher was
Full Post: Low-dose peginterferon used for hepatitis C doesn’t work
According to the latest research drinking alcohol shrinks the brain and the more alcohol an individual drinks, the smaller his or her total brain volume will be. The U.S. researchers say people who drink more than two glasses of wine a day are at a greater risk of suffering memory problems in old age than
Full Post: Alcohol linked to brain shrinkage
Most of the people who suffer from erectile dysfunction undergo a lot of stress and even end up separating with their partners because they cannot satisfy their sexual needs. Today there are several drugs in the market that can cure such problems easily therefore you do not need to be shy. Levitra being one of
Full Post: Levitra Vardenafil
A new study provides the first evidence of a link between alcohol-industry sponsorship and hazardous drinking among sportspeople. Researchers from The University of Manchester and the University of Newcastle in Australia quizzed nearly 1,300 sportspeople and found alcohol-related companies sponsored almost half of them. The sponsorship ranged from financial incentives, such as payment of
Full Post: Alcohol sponsorship linked to hazardous drinking in sportspeople
In the run up to the New Year’s Eve festivities a scientist in Britain has chosen an opportune moment to warn revellers that drinking alcohol, even in relatively small amounts, can increase a tipplers risk of developing cancer. Dr. Rachel Thompson, from the World Cancer Research Fund (WCRF) says that a large glass of
Full Post: Time to celebrate? Be warned! One tipple a day increases the risk of cancer